Isotechnika Pharma Inc. exercised its right to terminate the existing Development, Distribution and License Agreement with ILJIN. In doing so, Isotechnika secures full rights to voclosporin for transplant and autoimmune indications in the United States and other regions outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. The company already owns full rights in Europe.